SEC Form 6-K filed by PainReform Ltd.

This Report on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-257968 and 333-265902) and the Company’s Registration Statements on Form F-3 (Registration No. 333-282264, 333-254982, 333-276485 and 333-277594), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On October 10, 2024, the Board of PainReform Ltd. (the “Company”) appointed Mr. Eyal Broder as the Company’s Interim Chief Financial Officer until a replacement is appointed, replacing Dr. Ehud Geller, the current Executive Chairman of the Board, Interim Chief Executive Officer and Chief Financial Officer. Dr. Geller will continue to serve as the Executive Chairman of the Board and Interim Chief Executive Officer of the Company.

Prior to his appointment as our Interim Chief Financial Officer, Mr. Broder served as our Finance Director since February 2023. Previously, Mr. Broder served as Chief Financial Officer at several industry-leading companies, including Inomize, Tradenet Group, Elbit Imaging India and Koor Industries. Mr. Broder holds a BA in Accounting and Economics and an MBA in Business Management, both from Tel Aviv University.

As previously disclosed, the Company had received a notice on May 28, 2024, from the Nasdaq Listing Qualifications (“Nasdaq”) notifying the Company that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on Nasdaq, since the closing bid price for the Company’s ordinary shares listed on Nasdaq was below $1.00 for 30 consecutive trading days. On December 4, 2024, Nasdaq notified the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rules for continued listing.